Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany's Merck Scraps MS Drug Cladribine After Regulators' Rebuff

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck KGaA ends development of oral cladribine tablets following rejection by European and U.S. regulators.
Advertisement

Related Content

Diversification Fails To Protect Merck KGaA From Industry Pressures
Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market
Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review
Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market
Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono
Disappointing BRAVO Data Raise Doubts About Laquinimod’s Chances
Daclizumab Has Winning Efficacy In MS, But Safety Questions Linger
Struggling Merck Serono Pins Hopes On New Management, Organization
Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter
Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter

Topics

Advertisement
UsernamePublicRestriction

Register

PS072404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel